Founded with a mission to revolutionize oncology services, Haploscope aims to make cancer care more accessible, affordable, and simpler. The company offers a comprehensive digital platform that streamlines access to cancer care, support, clinical trial recruitment, cancer events, virtual tumor boards, medical ride-hailing, and second opinions. By focusing on breaking down barriers related to distance and demographics, Haploscope targets underserved and remote populations to ensure early detection and quality care.

Notable affiliated individuals include leading oncologists and healthcare professionals who contribute to the platform's development and implementation. Key investors are not publicly disclosed but are likely to include stakeholders passionate about healthcare innovation. Haploscope's significant achievements include the successful integration of various oncology services into a single cohesive platform, positively impacting patient outcomes and healthcare delivery. The company's overall impact lies in its ability to democratize cancer care, making it more accessible and efficient for patients worldwide.